for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Laboratorios Farmaceuticos ROVI SA

ROVI.MC

Latest Trade

21.10EUR

Change

-0.10(-0.47%)

Volume

686

Today's Range

20.50

 - 

21.30

52 Week Range

15.55

 - 

24.40

As of on the Mercado Continuo Espana ∙ Minimum 15 minute delay

Pricing

Previous Close
21.20
Open
20.50
Volume
686
3M AVG Volume
0.19
Today's High
21.30
Today's Low
20.50
52 Week High
24.40
52 Week Low
15.55
Shares Out (MIL)
55.38
Market Cap (MIL)
1,166.23
Forward P/E
47.02
Dividend (Yield %)
0.38

Latest Developments

More

Rovi H1 Net Profit Up At 16.2 Mln Euros YoY

Rovi Q1 Ebitda Up At 11.9 Mln Euros YoY

Rovi To Market Teva’s Osteoporosis Treatment For Adults In Spain

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Laboratorios Farmaceuticos ROVI SA

Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spain-based company principally engaged in the pharmaceutical industry. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The Company owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.

Industry

Biotechnology & Drugs

Contact Info

Calle Jose Isbert,2.

+34.913.756230

https://www.rovi.es/

Executive Leadership

Juan Lopez-Belmonte Lopez

Chairman of the Board

Juan Lopez-Belmonte Encina

Chief Executive Officer, Executive Director

Javier Lopez-Belmonte Encina

Second Vice Chairman of the Board, Chief Financial Officer, Executive Director

Ivan Jorge Lopez-Belmonte Encina

First Vice Chairman of the Board, Executive Director of Corporate Development

Pablo Dominguez Jorge

Chief Economic and Administrative Officer

Key Stats

2.73 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.3K

2017

0.3K

2018

0.3K

2019(E)

0.3K
EPS (EUR)

2016

0.455

2017

0.350

2018

0.350

2019(E)

0.451
Price To Earnings (TTM)
42.70
Price To Sales (TTM)
3.49
Price To Book (MRQ)
3.85
Price To Cash Flow (TTM)
30.53
Total Debt To Equity (MRQ)
16.40
LT Debt To Equity (MRQ)
11.51
Return on Investment (TTM)
9.38
Return on Equity (TTM)
6.96

Latest News

Latest News

BRIEF-Rovi Signs Distribution Agreement With Sandoz

* REACHES AGREEMENT WITH SANDOZ, A UNIT OF NOVARTIS, FOR DISTRIBUTION AND MARKETING OF ITS ENOXAPARIN BIOSIMILAR

BRIEF-ROVI FY Net Profit Down At 17.2 Mln Euros

LABORATORIOS FARMACEUTICOS ROVI SA (ROVI) :

BRIEF-Rovi Gets 45 Million Euro Loan From European Investment Bank

* GETS 45 MILLION EURO LOAN FROM EUROPEAN INVESTMENT BANK Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Rovi 9-month operating revenue up 6 pct at 203.4 mln euros YoY

* RECURRENT NET PROFIT DECREASED BY 4 PERCENT TO 17.0 MILLION EUROS IN 9-MONTH

BRIEF-Rovi announces update on risperidone project

* ANNOUNCES UPDATE ON A PHASE III STUDY FOR A LONG-ACTING INJECTABLE (LAI) TO TREAT SCHIZOPHRENIA CALLED DORIA(PREVIOUSLY RISPERIDONE ISM)

BRIEF-Rovi starts enoxaparin biosimilar marketing in Germany

* SAYS STARTS ENOXAPARIN BIOSIMILAR MARKETING IN GERMANY Source text for Eikon:

BRIEF-Rovi H1 Ebitda down 4 pct to 23.9 mln euros YoY

Laboratorios Farmaceuticos ROVI SA (ROVI):

BRIEF-Rovi Q1 net profit down at 6.4 mln euros

Laboratorios Farmaceuticos ROVI SA (ROVI):

BRIEF-Rovi to begin registration of its biosimilar enoxaparin in Europe

* Completes marketing authorization request procedure of its biosimilar enoxaparin in 26 European Union (EU) countries

BRIEF-Rovi signs deal to distribute Neparvis in Spain

* Signs deal with Novartis Farmaceutica to distribute Neparvis, a drug for symptomatic chronic heart failure, in Spain

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up